Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Mora

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
American Journal of Hematology|June 6, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
Blood Advances|August 11, 2020
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thrombosesPierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, et al.
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88<sup>L265P</sup> Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
Journal of Cellular and Molecular Medicine|July 21, 2025
CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in MyelofibrosisMargherita Mirabile, Camilla Tombari, Anita Neroni, et al.
American Journal of Hematology|July 2, 2024
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenograftsLara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, et al.
Hemasphere|February 26, 2026
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosisBarbara Mora, Matteo Franchi, Ludovica Margotto, et al.
Oncotarget|January 18, 2018
High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i>, <i>Lactobacillus gasseri/johnsonii</i>, and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiationRafael Guerrero-Preston, James Robert White, Filipa Godoy-Vitorino, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
British Journal of Haematology|March 5, 2024
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infectionRoberta Sciarra, Michele Merli, Caterina Cristinelli, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|June 6, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
Blood Advances|August 11, 2020
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thrombosesPierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, et al.
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88<sup>L265P</sup> Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
Journal of Cellular and Molecular Medicine|July 21, 2025
CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in MyelofibrosisMargherita Mirabile, Camilla Tombari, Anita Neroni, et al.
American Journal of Hematology|July 2, 2024
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenograftsLara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, et al.
Hemasphere|February 26, 2026
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosisBarbara Mora, Matteo Franchi, Ludovica Margotto, et al.
Oncotarget|January 18, 2018
High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i>, <i>Lactobacillus gasseri/johnsonii</i>, and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiationRafael Guerrero-Preston, James Robert White, Filipa Godoy-Vitorino, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
British Journal of Haematology|March 5, 2024
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infectionRoberta Sciarra, Michele Merli, Caterina Cristinelli, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Pageof 7